Food and Drug Administration
Biological Response Modifiers Advisory Committee
October 25, 2001
Slides
Lentiviral Vectors, Gene Therapy, Dr. Inder Verma, Salk Institute for Biological Studies ppt htm
Lentiviral Vectors: Safety Issues, Daniel Takefman, PhD, FDA ppt htm
Safety Features in the Design, Manufacture and Clinical Monitoring of Lentivectors for the Treatment of Parkinson's Disease, Prostate Cancer and Aids, Susan M Kingsman, Oxford BioMedica (UK) Ltd. ppt htm
Predicting Lentiviral Vector Safety In Vivo, Dr. John Kappes, University of Alabama at Birmingham ppt htm